Reactions Weekly

, Volume 1722, Issue 1, pp 298–298 | Cite as

Protein tyrosine kinase inhibitors

Acquired resistance in non-small cell lung cancer and phenotype switch to small cell lung cancer: 4 case reports
Case report


  1. Fumagalli C, et al. The immune profile of EGFR-mutated non-small-cell lung cancer at disease onset and progression after tyrosine kinase inhibitors therapy. Immunotherapy 10: 1041-1045, No. 12, Sep 2018. Available from: URL: - ItalyCrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations